Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

ClinicalTrials.gov ID: NCT00074490

Public ClinicalTrials.gov record NCT00074490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 12, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome

Study identification

NCT ID
NCT00074490
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
442 participants

Conditions and interventions

Interventions

  • Allogeneic hematopoietic stem cell transplant (HSCT) Procedure
  • Cyclophosphamide Drug
  • Doxorubicin Drug
  • Etoposide Drug
  • Filgrastim Drug
  • Fludarabine Drug
  • Peripheral blood stem cell (PBSC) transplantation Procedure
  • Prednisone Drug
  • Rituximab Drug
  • T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells Genetic
  • T-Rapa cell Donor Lymphocyte Infusion (DLI) Genetic
  • Vincristine Drug

Procedure · Drug · Genetic

Eligibility (public fields only)

Age range
11 Years to 90 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2003
Primary completion
Jul 19, 2017
Completion
Aug 15, 2017
Last update posted
Dec 30, 2018

2004 – 2017

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland 20892 —
Hackensack University Medical Center Hackensack New Jersey 07601 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00074490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 30, 2018 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00074490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →